Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
6,450€
-3,37%
Echtzeit-Aktienkurs Enanta Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Enanta Pharmaceuticals Inc. Aktie
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 9.48% and 5.93%, respectively, for the quarter ended December 2024. Do…
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript
…